CEO Marc Voigt said: “We are very excited to be working alongside CYTLIMIC to help evaluate efti as part of an innovative cancer vaccine that has potential as a new therapy.
Efti is generating interest globally. Following the agreements with CYTLIMIC, it is now being evaluated as part of three different combination therapy types: as part of a therapeutic cancer vaccine, as a chemo-immunotherapy and in an IO combination, showing its broad therapeutic potential.”
Ann: Immutep enters into collaboration with CYTLIMIC, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.015(5.26%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.8¢ | 29.0¢ | $833.7K | 2.793M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 258479 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 221018 | 27 |
View Market Depth
| Last trade - 15.13pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
